---
title: "SSY Group Sees Reduction In FY Profit Attributable In Range Of 45% To 60%"
description: "SSY Group Ltd :SSY GROUP SEES REDUCTION IN FY PROFIT ATTRIBUTABLE IN RANGE OF 45% TO 60%EXPECTED RESULT DUE TO DECLINE IN TURNOVER, OTHERS IN FY"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276050746.md"
published_at: "2026-02-16T10:36:59.000Z"
---

# SSY Group Sees Reduction In FY Profit Attributable In Range Of 45% To 60%

> SSY Group Ltd :SSY GROUP SEES REDUCTION IN FY PROFIT ATTRIBUTABLE IN RANGE OF 45% TO 60%EXPECTED RESULT DUE TO DECLINE IN TURNOVER, OTHERS IN FY

SSY Group Ltd :

-   SSY GROUP SEES REDUCTION IN FY PROFIT ATTRIBUTABLE IN RANGE OF 45% TO 60%
-   EXPECTED RESULT DUE TO DECLINE IN TURNOVER, OTHERS IN FY

### Related Stocks

- [159570.CN - China Universal CNI HK Connect Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159570.CN.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)
- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [300765.CN - CSPC Innovation](https://longbridge.com/en/quote/300765.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [513060.CN - Bosera Hang Seng Health Care ETF(QDII)](https://longbridge.com/en/quote/513060.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| AsymBio Launches Integrated Biopharma Platforms for End-to-End Development | AsymBio, a subsidiary of Asymchem Laboratories Tianjin Co. Ltd., has launched integrated technology platforms for the en | [Link](https://longbridge.com/en/news/275471539.md) |
| Beijing Tong Ren Tang Chinese Medicine Co. Ltd. Held Extraordinary General Meeting | Beijing Tong Ren Tang Chinese Medicine Co. Ltd. held an extraordinary general meeting on February 11, 2026, where all pr | [Link](https://longbridge.com/en/news/275583242.md) |
| Abbisko Cayman Board to Approve Audited Annual Results and Consider Final Dividend | Abbisko Cayman Ltd. will hold a board meeting on March 2, 2026, to approve its audited annual results for the year endin | [Link](https://longbridge.com/en/news/275573355.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.